Cellebrite DI Ltd. Appoints Interim CEO Amid Leadership Transition
Ticker: CLBT · Form: 6-K · Filed: Jan 6, 2025 · CIK: 1854587
| Field | Detail |
|---|---|
| Company | Cellebrite Di Ltd. (CLBT) |
| Form Type | 6-K |
| Filed Date | Jan 6, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, interim-ceo, governance
TL;DR
Cellebrite's Chairman, Thomas E. Hogan, is now interim CEO as of Jan 1, 2025, in a planned leadership shuffle.
AI Summary
On January 1, 2025, Thomas E. Hogan, the current chairman of the board of directors for Cellebrite DI Ltd., began serving as interim CEO. This change is part of a planned leadership transition and reflects the company's commitment to strong board governance, particularly regarding the separation of duties between the CEO and the chairman roles.
Why It Matters
This leadership change could signal strategic shifts or operational adjustments within Cellebrite DI Ltd. as they navigate a planned transition.
Risk Assessment
Risk Level: low — The filing describes a planned leadership transition, which is a routine corporate event and not indicative of immediate financial distress or significant operational risk.
Key Players & Entities
- Cellebrite DI Ltd. (company) — Registrant
- Thomas E. Hogan (person) — Chairman of the board and interim CEO
- January 1, 2025 (date) — Effective date of interim CEO appointment
FAQ
Who has been appointed as the interim CEO of Cellebrite DI Ltd.?
Thomas E. Hogan, the current chairman of the board of directors, began serving as interim CEO.
When did the leadership transition take effect?
The transition took effect on January 1, 2025.
What is the primary reason for this leadership change?
The change is part of a planned leadership transition and Cellebrite's commitment to best practices in board governance, specifically regarding the separation of duties.
What is Cellebrite DI Ltd.'s principal executive office address?
The principal executive office is located at 94 Shlomo Shmelzer Road, Petah Tikva 4970602, Israel.
Does Cellebrite DI Ltd. file annual reports under Form 20-F or Form 40-F?
Cellebrite DI Ltd. files annual reports under Form 20-F.
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-01-06 08:15:02
Filing Documents
- ea0226832-6k_cellebrite.htm (6-K) — 16KB
- ea022683201ex99-1_cellebrite.htm (EX-99.1) — 16KB
- 0001213900-25-000949.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Cellebrite DI Ltd. Date: January 6, 2025 By: /s/ Ayala Berler Shapira Ayala Berler Shapira, Adv. General Counsel 3